Celecoxib and colon cancer

New York, June 30, 2000 (Praxis Press) In familial adenomatous polyposis (FAP), a genetic disease that spurs the formation of hundreds of adenomatous polyps in the colon, the risk of developing colorectal cancer verges on 100 percent. Nonsteroidal antiinflammatory drugs (NSAIDs) are linked to a lower incidence of adenomatous polyps and lower colon cancer mortality, possibly due to their inhibition of the cyclooxygenase enzyme family, but their gastrointestinal toxicity limits their long-term use

June 30, 2000

New York, June 30, 2000 (Praxis Press) In familial adenomatous polyposis (FAP), a genetic disease that spurs the formation of hundreds of adenomatous polyps in the colon, the risk of developing colorectal cancer verges on 100 percent. Nonsteroidal antiinflammatory drugs (NSAIDs) are linked to a lower incidence of adenomatous polyps and lower colon cancer mortality, possibly due to their inhibition of the cyclooxygenase enzyme family, but their gastrointestinal toxicity limits their long-term use. In a recent study published in The New England Journal of Medicine, a six-month twice-daily treatment with 400 mg of celecoxib, a specific cyclooxygenase-2 inhibitor not associated with the gastric ulceration linked to traditional NSAIDs, significantly reduced the number of colorectal polyps in patients with FAP (see paper). After six months, patients had a 28 percent reduction in the mean number of colorectal polyps and a 30.7 percent reduction in the polyp burden. These findings suggest that celecoxib may become part of the pharmacologic strategy for the prevention of colorectal adenomas, once its long-term effects are evaluated.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham